Related Experiment Video
Updated: Aug 8, 2026
A 3D System for Culturing Human Articular Chondrocytes in Synovial Fluid
Published on: January 31, 2012
[Preliminary study of TRPV4 affects chondrocyte degeneration]
Xue Shen1, Hu Zhang1, De-Ta Chen2
1Shuguang Hospital Affiliated to Shanghai University of Traditiontal Chinese Medicine, Shanghai 201203, China.
Objective:
To explore and verify that transient receptor potential vanilloid 4(TRPV4) affects chondrocyte degeneration.
Methods:
Neonatal SD rats were selected, primary chondrocytes were extracted, and identified by toluidine blue staining and alcian blue staining;an in vitro chondrocyte inflammation model was constructed by IL-1β, and TRPV4 inhibitor was used to treat chondrocytes under inflammatory conditions, and the chondrocytes were treated by RT-PCR method was used to detect matrix metallopeptidase 13(MMP-13), a disintegrin and metalloproteinase with thrombospondin 5, (ADAMTS-5)、nitric oxide synthase 2(NOS2)、Collagen, type II alpha 1(Col2α1)and aggrecan (Acan) mRNA in chondrocytes; primary chondrocytes were treated with different concentrations of TRPV4 overexpression plasmid, and the optimal overexpression dose was screened. The mRNA expressions of TRPV4, MMP-13, ADAMTS-5, NOS2, Col2α1 and Acan in chondrocytes under the optimal TRPV4 overexpression dose were detected.
Results:
Toluidine blue staining and Alcian blue staining identified the extracted cells as primary chondrocytes;RT-PCR showed that TRPV4, MMP-13, ADAMTS-5, NOS2 mRNA in chondrocytes treated with TRPV4 inhibitor under inflammatory conditions. The expression of Col2α1 mRNA was significantly decreased (P<0.05), and the expression of Col2α1 mRNA was increased (P<0.05). Although there was no significant difference in the expression of Acan mRNA, the overall trend was also increasing. The expression of Col2α1 and Acan mRNA in chondrocytes was significantly decreased (P<0.05), and the expression of NOS2 mRNA was increased(P<0.05), but there was no significant difference in MMP-13 and ADAMTS-5 (P>0.05).
Conclusion:
Inhibiting the expression of TRPV4 can down-regulate the expression of genes related to chondrocyte degeneration.
Insights
Inhibiting transient receptor potential vanilloid 4 (TRPV4) reduces genes linked to chondrocyte degeneration. This finding offers potential therapeutic targets for cartilage diseases.
Area of Science:
- Cell Biology
- Molecular Biology
- Biochemistry
Context:
- Chondrocyte degeneration is a hallmark of osteoarthritis and other cartilage diseases.
- The role of transient receptor potential vanilloid 4 (TRPV4) in chondrocyte health and disease is not fully understood.
- Understanding the molecular mechanisms underlying chondrocyte degeneration is crucial for developing effective treatments.
Purpose:
- To investigate the effect of transient receptor potential vanilloid 4 (TRPV4) on chondrocyte degeneration.
- To determine if inhibiting TRPV4 can prevent or reverse chondrocyte damage.
- To identify specific genes regulated by TRPV4 in chondrocytes.
Summary:
- Primary chondrocytes were isolated and an in vitro inflammation model was established using IL-1β.
- Treatment with a TRPV4 inhibitor under inflammatory conditions led to decreased expression of Collagen, type II alpha 1 (Col2α1) and increased nitric oxide synthase 2 (NOS2) mRNA.
- Overexpression of TRPV4 resulted in decreased Col2α1 and Acan mRNA expression and increased NOS2 mRNA expression, indicating TRPV4's role in regulating chondrocyte matrix components and inflammatory response.
Impact:
- Inhibiting TRPV4 expression down-regulates genes associated with chondrocyte degeneration, suggesting TRPV4 as a potential therapeutic target.
- This research provides insights into the molecular pathways involved in cartilage degeneration.
- Findings could inform the development of novel strategies for treating osteoarthritis and other chondrocyte-related disorders.
